

FDA nod for Aurobindo's acid reflux treatment drug

28 December 2015 | News | By BioSpectrum Bureau

FDA nod for Aurobindo's acid reflux treatment drug



Aurobindo Pharma announces that the company has received final approval from the US Food and Drug Administration (USFDA) to manufacture and market Famotidine Tablets USP, 20 mg and 40 mg.

The approved ANDA is bioequivalent and therapeutically equivalent to the reference listed drug product (RLD) Pepcid Tablets, 20 mg and 40 mg, of Valeant Pharmaceuticals International.

Famotidine Tablets is used for the short-term treatment of gastroesophageal reflux disease and active duodenal ulcer. The approved product has an estimated market size of \$29 million for the twelve months ending October 2015 according to IMS.